Takeda To Expand Operations In Mexico, Turkey, Europe

Takeda will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries – Takeda Pharmaceuticals Mexico, Takeda Pharmaceuticals Trade (Turkey), Takeda Pharmaceuticals Nordics (Sweden), and Takeda Pharmaceuticals Benelux (Belgium) – are part of Takeda’s strategic global expansion efforts.

Alan MacKenzie, executive vice president of international operations at Takeda Pharmaceuticals International, said: “Takeda has a significant opportunity to expand our presence in Mexico, Europe and other priority markets. Executing our territory expansion strategy is an important step toward further globalising our operations and enhancing our ability to bring important medicines to patients who need them.”

Following the buy-back of Actos (pioglitazone) in October 2008, Takeda will be distributing Actos in the five countries (Norway, Sweden, Denmark, Belgium and Luxembourg). The creation of these commercial subsidiaries will further increase Takeda’s reach in the regions.

Takeda also recently re-acquired the rights to Actos in the Turkish market, providing the business with a strong product to enter the market.

Reportedly, the new subsidiaries will accelerate Takeda’s expansion efforts for core products including Actos and reinforces Takeda’s global operating infrastructure. The company will work toward the earliest possible approval and launch of new products in these regions. Takeda’s presence in these seven new countries builds upon other expansions announced in 2009 including commercial operations in Spain, Portugal, Ireland, and Canada.